U.S. Approves First Single-Dose Generic Flu Drug, Adding Options for Fall and Winter Treatment
A generic version of baloxavir marboxil has been approved for launch before the 2026 to 2027 flu season. Its significance lies not in changing the principles of treatment, but in potentially making a once-daily antiviral option more accessible in clinical and home-care settings.